PMID- 18523770
OWN - NLM
STAT- MEDLINE
DCOM- 20090113
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 58
IP  - 2
DP  - 2009 Feb
TI  - The antitumor immune responses induced by nanoemulsion-encapsulated 
      MAGE1-HSP70/SEA complex protein vaccine following peroral administration route.
PG  - 201-8
LID - 10.1007/s00262-008-0539-9 [doi]
AB  - Previous studies have shown that there are profuse lymphatic tissues under the 
      intestinal mucous membrane. Moreover, vaccine administered orally can elicit both 
      mucous membrane and system immune response simultaneously, accordingly induce 
      tumor-specific cytotoxic T lymphocyte. As a result, the oral route is constituted 
      the preferred immune route for vaccine delivery theoretically. However, numerous 
      vaccines especially protein/peptide vaccines remain poorly available when 
      administered by this route. Nanoemulsion has been shown as a useful vehicle can 
      be developed to enhance the antitumor immune response against antigens 
      encapsulated in it and it is good for the different administration routes. Of 
      particular interest is whether the protein vaccine following peroral route using 
      nanoemulsion as delivery carrier can induce the same, so much as stronger 
      antitumor immune response to following conventional ways such as subcutaneous 
      (sc.) or not. Hence, in the present study, we encapsulated the MAGE1-HSP70 and 
      SEA complex protein in nanoemulsion as nanovaccine NE (MHS) using magnetic 
      ultrasound method. We then immuned C57BL/6 mice with NE (MHS), MHS alone or NE 
      (-) via po. or sc. route and detected the cellular immunocompetence by using 
      ELISpot assay and LDH release assay. The therapeutic and tumor challenge assay 
      were examined then. The results showed that compared with vaccination with MHS or 
      NE (-), the cellular immune responses against MAGE-1 could be elicited fiercely 
      by vaccination with NE (MHS) nanoemulsion. Furthermore, encapsulating MHS in 
      nanoemulsion could delay tumor growth and defer tumor occurrence of mice 
      challenged with B16-MAGE-1 tumor cells. Especially, the peroral administration of 
      NE (MHS) could induce approximately similar antitumor immune responses to the sc. 
      administration, but the MHS unencapsulated with nanoemulsion via po. could induce 
      significantly weaker antitumor immune responses than that via sc., suggesting 
      nanoemulsion as a promising carrier can exert potent antitumor immunity against 
      antigen encapsulated in it and make the tumor protein vaccine immunizing via po. 
      route feasible and effective. It may have a broad application in tumor protein 
      vaccine.
FAU - Ge, Wei
AU  - Ge W
AD  - State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital, 
      Fourth Military Medical University, Xi'an, 710032, Shaanxi Province, China. 
      geweidr@fmmu.edu.cn
FAU - Li, Yuan
AU  - Li Y
FAU - Li, Zeng-Shan
AU  - Li ZS
FAU - Zhang, Shan-Hong
AU  - Zhang SH
FAU - Sun, Yu-Jing
AU  - Sun YJ
FAU - Hu, Pei-Zhen
AU  - Hu PZ
FAU - Wang, Xiao-Ming
AU  - Wang XM
FAU - Huang, Yang
AU  - Huang Y
FAU - Si, Shao-Yan
AU  - Si SY
FAU - Zhang, Xiu-Min
AU  - Zhang XM
FAU - Sui, Yan-Fang
AU  - Sui YF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080604
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Emulsions)
RN  - 0 (HSP70 Heat-Shock Proteins)
RN  - 0 (MAGEA1 protein, human)
RN  - 0 (Melanoma-Specific Antigens)
RN  - 0 (Neoplasm Proteins)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Antigens, Neoplasm/administration & dosage/immunology/*pharmacology
MH  - Cancer Vaccines/administration & dosage/immunology/*pharmacology/toxicity
MH  - Cell Line, Tumor
MH  - Drug Administration Routes
MH  - Emulsions/administration & dosage/pharmacology
MH  - HSP70 Heat-Shock Proteins/administration & dosage/immunology/*pharmacology
MH  - Lymphocyte Activation
MH  - Melanoma-Specific Antigens
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - *Nanoparticles/ultrastructure
MH  - Neoplasm Proteins/administration & dosage/immunology/*pharmacology
MH  - T-Lymphocytes/immunology
PMC - PMC11030077
EDAT- 2008/06/05 09:00
MHDA- 2009/01/14 09:00
PMCR- 2008/06/04
CRDT- 2008/06/05 09:00
PHST- 2008/02/09 00:00 [received]
PHST- 2008/05/20 00:00 [accepted]
PHST- 2008/06/05 09:00 [pubmed]
PHST- 2009/01/14 09:00 [medline]
PHST- 2008/06/05 09:00 [entrez]
PHST- 2008/06/04 00:00 [pmc-release]
AID - 539 [pii]
AID - 10.1007/s00262-008-0539-9 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2009 Feb;58(2):201-8. doi: 10.1007/s00262-008-0539-9. 
      Epub 2008 Jun 4.